Comparative Outcomes and Molecular Response Predictors of IDH1/2-mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)
      Google Scholar   
Citation:
Blood vol 138 (Supplement 1) 226
Meeting Instance:
ASH 2021
Year:
2021
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171;  
Corr. Author:
 
Authors:
                                                       
Networks:
CA043, FL065, LAPS-AL002, LAPS-MA036, LAPS-OH007, LAPS-PA015, LAPS-TX011, MD015, NC002, NORTHWELL, OH008, OH070   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-20202, CALGB-8461, CALGB-9665
Phases:
N/A
Keywords: